EUDA Announces Collaboration to Advance an Integrated iPSC Cell Therapy Program for Oncology and Wellness

Hi folks,

I'm bringing you an important update on EUDA Health (Nasdaq: EUDA).

EUDA today announced new details surrounding its previously disclosed strategic collaboration to advance an integrated induced pluripotent stem cell (iPSC) therapy platform focused on both oncology and wellness.

The initiative brings together three organizations with complementary expertise in regenerative medicine, cell engineering, manufacturing, and commercialization—creating what could become a meaningful long-term platform for next-generation cell therapies.

News Link Here – Snapshot Below

EUDA Health Announces Collaboration to Advance an Integrated iPSC Cell Therapy Program for Oncology and Wellness Targets global distribution for innovative Oncology products

According to today's announcement, the collaboration is designed to combine advanced stem cell technology, engineered immune cell development, and commercial infrastructure to support the future development of innovative off-the-shelf cell therapies.

Here's how each partner contributes:

EUDA Health

• Intends to coordinate the collaboration between the parties.
• Plans to fund the joint initiative.
• Will support commercialization efforts and global market expansion.

GO POSB

• Provides its proprietary iPSC platform and tumor organoid bank.
• Will assist with commercialization of the technologies being developed.

SIIT

• Brings advanced Natural Killer (NK) and NK-TCR cell engineering capabilities.
• Provides expertise in genetic engineering, GMP manufacturing, quality testing, and production through its Shenzhen facility.

Why This Matters

Cell therapy remains one of the fastest-growing areas of modern biotechnology, with researchers working to develop treatments that can be manufactured at scale and delivered to patients more efficiently than traditional personalized therapies.

The companies intend to explore the development of off-the-shelf iPSC-derived cell therapies—an approach designed to simplify manufacturing while potentially expanding patient access if successfully developed and approved.

By combining stem cell technology, immune-cell engineering, and commercial expertise under one collaboration, EUDA is positioning itself to participate in a rapidly evolving segment of regenerative medicine.

CEO Commentary

CEO Alfred Lim emphasized that bringing together these three specialized organizations represents an important milestone toward developing future commercial cell therapy products.

He also noted that, if successful, standardized off-the-shelf therapies could represent a significant advancement over existing treatment approaches while helping build long-term shareholder value.

Wall Street analysts are closely watching EUDA's expanding pipeline of healthcare catalysts, including next-generation TCR-T cell therapy targeting solid tumors.

Analysts issue a $55 price target on EUDA representing 175%+ upside potential, based on analyst's estimate.

EUDA is one to watch right now, technical indicators are signaling a favorable setup based on Investing.com technical analysis.

EUDA is one to watch right now. With a reported public float of just 1.11M shares, could EUDA become the next low-float stock to capture traders' attention—similar to some of my previous breakout alerts?

Remember my previous low float breakout DFNS which I alerted pre-market at approx. $6.87 on July 27, today it rocketed to a pre-market high of $96.56 for a +1,305% gain from my alert.

While every stock is different and past performance doesn't predict future results, low-float companies with compelling catalysts are often the ones I watch most closely.

With a reported low public float and multiple catalysts beginning to take shape, I believe EUDA deserves a spot on your watchlist. Keep a close eye on EUDA as this story continues to unfold.

To Your Success,